Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9NWK9
UPID:
BCD1_HUMAN
Alternative names:
Serologically defined breast cancer antigen NY-BR-75; Zinc finger HIT domain-containing protein 6
Alternative UPACC:
Q9NWK9; B2RBA1; B4DP13; D3DT20; Q9H278; Q9H3X3; Q9NWN0
Background:
Box C/D snoRNA protein 1, also known as Serologically defined breast cancer antigen NY-BR-75 and Zinc finger HIT domain-containing protein 6, plays a crucial role in the accumulation of box C/D snoRNAs. These snoRNAs are essential for snoRNA processing, transport to the nucleolus, and ribosome biogenesis, highlighting the protein's significance in cellular machinery.
Therapeutic significance:
Understanding the role of Box C/D snoRNA protein 1 could open doors to potential therapeutic strategies. Its involvement in fundamental cellular processes underscores its potential as a target for drug discovery, aiming to modulate ribosome biogenesis and snoRNA processing.